FindTrial
Sign In

Hydroxychloroquine retinopathy in patients with Rheumatic Diseases.

The Incidence of Retinopathy in Rheumatic and Musculoskeletal Disease patients on long term Hydroxychloroquine (HCQ) use - A Prospective Study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028459
Enrollment
500
Registered
2020-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M138- Other specified arthritis

Interventions

Intervention1: HYDROXYCHLOROQUINE: 200 mg per day Route of Administration - Oral Duration : At least 05 years Control Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Arindam Nandy Roy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Able to provide signed consent form. Subjects clinically diagnosed to have rheumatic and musculoskeletal diseases. Subjects willing to take HCQ for long duration

Exclusion criteria

Exclusion criteria: 1. Preexisting ocular conditions of the anterior segment or the retina causing defective vision. 2. Are taking a medication other than HCQ with retinotoxic side effects (Tamoxifen). 3. Known hypersensitivity to 4-aminoquinoline compounds (such as Chloroquine or hydroxychloroquine). 4. Previous exposure to HCQ.

Design outcomes

Primary

MeasureTime frame
To identify the incidence and risk factors of retinopathy in patients of rheumatic and musculoskeletal diseases using long term HCQ by modern screening methods.Timepoint: After 01 year( later each year )—

Secondary

MeasureTime frame
Skin hyper pigmentationTimepoint: after 06 months—

Countries

India

Contacts

Public ContactDr Arindam Nandy Roy

Yashoda Hospitals

doctor.arindam@yahoo.com9849279830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026